Cancer cell

Perspectives

Look again. New ways to fight cancer.

From early detection to treatment and cures

Cancer care is changing fast. Breakthroughs in treatments, payment and commercial models, research and development, regulation, and much more are all rapidly evolving. We at Deloitte are involved in this transformation and committed to leveraging our capabilities, experience, and ecosystems to innovate and collaborate to find a cure for cancer. We are focused on applying innovative technologies and analytics as mechanisms to improve the quality of oncology care.

Fighting cancer through early detection: Deloitte XPRIZE to serve as a catalyst for change in cancer

Deloitte Cancer XPRIZE certified by XPRIZE as “ready for launch”

Saving millions of lives globally from cancer is one step closer to a reality as Deloitte’s Cancer XPRIZE, co-led by Deloitte health leaders and pediatric oncologist Dr. Daniel Kraft, is now officially “ready for launch.” XPRIZE convened nine international teams to share their impact design proposals across a portfolio of grand challenge areas at the Visioneers 2016 Summit. Now, Deloitte is working with XPRIZE to create a scientific advisory board, and hopes to fully fund and launch the competition in 2018.

About the XPRIZE

Teams will develop a means to accurately, rapidly, and affordably screen for early cancer where intervention can not only decrease human suffering but potentially foster an environment where we can truly conquer cancer.The prize will address market failures of siloed ecosystems, regulatory complexity, misaligned incentives and barriers to entry for new ideas.

Accurately: A solution must be sensitive to detect cancer early enough for effective intervention, yet specific to avoid over-diagnosis.

Rapidly: Reducing or eliminating the time between a test being conducted and the delivery of its results is key to addressing disparities in cancer screening.

Affordably: Significantly reducing the cost of cancer screening is key to making it more available.

The evolution of oncology payment models: What can we learn from early experiments?

Pioneering health plans and provider groups are experimenting with value-based payment models in oncology to try to improve the cost-effectiveness of cancer care. They are piloting these models in the commercial market—financial incentives for adhering to clinical pathways, patient-centered medical homes (PCMHs), bundled payments, and accountable care organizations—and it is uncertain which will achieve the dual goals of improving outcomes and controlling costs.

We interviewed health plans and providers participating in emerging payment models to review early results (financial and clinical), understand which approaches are working, and discuss considerations for these models’ future evolution.

Back to top

Commercializing curative therapies: Challenges and implications for biopharmaceutical companies

Advances in the understanding of disease biology combined with the development of new treatment modalities, including gene and cell therapy, are paving the way for a paradigm shift—from managing a disease to curing it. However, developing and manufacturing cures and treatments for complex diseases can be a daunting and costly process.

Companies ushering potentially curative treatments to market will need to navigate an outdated reimbursement model and a distinct set of challenges related to pricing and market access, biopharma resourcing models, and (for complex treatments) the health care delivery system and manufacturing/supply chain.

Back to top

Top 10 health care innovations: More value, better outcomes, for less

Health care is an industry in need of innovation. Health plans, providers, life sciences companies, and the government are facing rising costs and inconsistent outcomes. They are working to improve care and health outcomes, all while reducing costs and spending. What innovations are most likely to help stakeholders achieve these goals and transform health care over the next 10 years?

Back to top

How we are helping clients with oncology challenges

To help cure cancer, health care stakeholders will need to leverage new innovations and new relationships. As one the world’s leading life sciences and health care consulting firm, we work with every stakeholder in the cancer ecosystem, from nonprofit advocacy groups to the world’s premier cancer centers. Deloitte is a trusted advisor to federal health agencies, hospitals and health systems, health plans, and biopharmaceutical and medical device companies.

These connections can provide the glue needed to build a network—an ecosystem—of collaborators who can re-architect cancer research and discovery in a holistic manner.

Back to top

In the news:

Nine teams propose XPRIZE competitions to address grand challenges at Visioneers Summit
All teams result in viable future XPRIZE concepts, with top three teams certified as “ready for launch” in the areas of cancer, avatars, and ALS.

The Cancer Moonshot initiative: Taking a giant leap toward a cure
Dr. Terri Cooper, Federal Health leader, discusses her experience at the Cancer Moonshot Summit in this issue of Health Care Current.

Deloitte’s response to Vice President’s Cancer Moonshot call to action
In response to the Cancer Moonshot call to action, Deloitte is designing an XPRIZE in cancer.

White House Fact Sheet announcing Deloitte’s Cancer Moonshot XPRIZE
Deloitte Consulting LLP is working alongside players across the cancer ecosystem, from governments to non-profit advocacy groups, and from R&D to health care delivery, to facilitate the development and improvement of cancer diagnosis, treatment, and care.

Back to top

microphone

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?